Vo, H.H.; Cartwright, C.; Song, I.-W.; Karp, D.D.; Nogueras Gonzalez, G.M.; Xie, Y.; Karol, M.; Hitron, M.; Vining, D.; Tsimberidou, A.-M.
Ipilimumab, Pembrolizumab, or Nivolumab in Combination with BBI608 in Patients with Advanced Cancers Treated at MD Anderson Cancer Center. Cancers 2022, 14, 1330.
https://doi.org/10.3390/cancers14051330
AMA Style
Vo HH, Cartwright C, Song I-W, Karp DD, Nogueras Gonzalez GM, Xie Y, Karol M, Hitron M, Vining D, Tsimberidou A-M.
Ipilimumab, Pembrolizumab, or Nivolumab in Combination with BBI608 in Patients with Advanced Cancers Treated at MD Anderson Cancer Center. Cancers. 2022; 14(5):1330.
https://doi.org/10.3390/cancers14051330
Chicago/Turabian Style
Vo, Henry Hiep, Carrie Cartwright, I-Wen Song, Daniel D. Karp, Graciela M. Nogueras Gonzalez, Yuran Xie, Michael Karol, Matthew Hitron, David Vining, and Apostolia-Maria Tsimberidou.
2022. "Ipilimumab, Pembrolizumab, or Nivolumab in Combination with BBI608 in Patients with Advanced Cancers Treated at MD Anderson Cancer Center" Cancers 14, no. 5: 1330.
https://doi.org/10.3390/cancers14051330
APA Style
Vo, H. H., Cartwright, C., Song, I.-W., Karp, D. D., Nogueras Gonzalez, G. M., Xie, Y., Karol, M., Hitron, M., Vining, D., & Tsimberidou, A.-M.
(2022). Ipilimumab, Pembrolizumab, or Nivolumab in Combination with BBI608 in Patients with Advanced Cancers Treated at MD Anderson Cancer Center. Cancers, 14(5), 1330.
https://doi.org/10.3390/cancers14051330
